Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LD-OXIRI in Metastatic Pancreatic Cancer
NCT05929885Phase 2Recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Aug 2023
- Primary completion
- Feb 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic cancer (PC), sponsored by National Cancer Centre Singapore. Started Aug 2023; status: recruiting.
02
Drugs
capecitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05929885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929885.